Compassionate use of vonsetamig
This trial provides access to an investigational medicine called vonsetamig for patients who have no other treatment options. It is a compassionate use program, meaning it is for people with serious conditions who cannot join a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a serious or life-threatening condition.
- You must have tried all approved treatments without success.
- You cannot join a standard clinical trial.
- Your doctor must apply for you and provide medical records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
This Phase 1 trial tests whether combining two targeted antibody medicines—cevostamab and elranatamab—is safe and whether it shows signs of activity in people whose multiple myeloma has come back or not responded. It’s early-stage, so the main goal is safety, dosing, and how the medicines behave in the body.
This trial tests a new cell therapy called UB-VV500 combined with rapamycin for people whose multiple myeloma has returned or not responded to at least three prior treatments. The goal is to see if this combination can help control the cancer.
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
Hear when a new Plasma Cell Mediated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.